SOPH SOPHiA GENETICS S.A.
QT69Latest market price
7.63
-0.34-4.27%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.15 | Insider Own | 9.56% | Shs Outstand | 85.13M | Perf Week | 3.81% |
| Market Cap | 649.53M | Forward P/E | — | EPS next Y | -0.63 | Insider Trans | -7.57% | Shs Float | 65.47M | Perf Month | -4.98% |
| Enterprise Value | 600.53M | PEG | — | EPS next Q | -0.20 | Short Float | 1.53% | Perf Quarter | 34.09% | ||
| Income | -80.00M | P/S | 7.55 | EPS this Y | — | Short Ratio | 1.71 | Perf Half Y | 43.42% | ||
| Sales | 86.00M | P/B | 7.83 | EPS next Y | — | ROA | -40.77% | Short Interest | 1.00M | Perf YTD | 63.38% |
| Book/sh | 0.97 | P/C | 6.01 | EPS next 5Y | — | ROE | -136.71% | 52W High | 8.98 -15.03% | Perf Year | 68.06% |
| Cash/sh | 1.27 | P/FCF | — | EPS past 3/5Y | — | ROIC | -48.83% | 52W Low | 3.83 99.22% | Perf 3Y | 107.90% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 17.06% 22.42% | Gross Margin | 66.63% | Volatility | 4.95% 6.61% | Perf 5Y | -50.52% |
| Dividend TTM | — | EV/Sales | 6.98 | EPS Y/Y TTM | — | Oper. Margin | -85.01% | ATR (14) | 0.47 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.55 | Sales Y/Y TTM | 22.86% | Profit Margin | -93.86% | RSI (14) | 51.57 | Recom | 2.13 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.69 | EPS Q/Q | -178.79% | SMA20 | 4.14% | Beta | 1.06 | Target Price | 11.50 |
| Payout | 0.00% | Debt/Eq | 0.71 | Sales Q/Q | 27.78% | SMA50 | -3.09% | Rel Volume | 0.62 | Prev Close | 7.97 |
| Employees | 415 | LT Debt/Eq | 0.71 | Earnings | Nov 03 | SMA200 | 28.24% | Avg Volume | 610.26K | Price | 7.63 |
| IPO Date | Jul 23, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -23.79% 7.32% | Net Debt/EBITDA | — | Volume | 378,986 | Change | -4.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | BTIG | Buy | $8.00 → $9.00 |
| Aug-05-26 | Reiterated | HC Wainwright & Co. | Buy | $12 → $14 |
| Jul-20-26 | Initiated | H.C | Buy | $12 |
| Apr-15-26 | Reiterated | BTIG | Buy | $7.00 → $8.00 |
| Mar-03-26 | Reiterated | BTIG | Buy | $5.00 → $7.00 |
| Jan-26-26 | Reiterated | Guggenheim | Buy | $6.00 → $7.00 |
| Mar-06-25 | Reiterated | BTIG | Buy | $6.00 → $5.00 |
| Aug-07-24 | Reiterated | Morgan Stanley | Overweight | $5.00 |
| Jun-27-24 | Reiterated | Guggenheim | $6.00 | |
| Jan-03-23 | Reiterated | BTIG | Buy | $6.00 |
Latest News· Times ET
Oct-20-26
Oct-20-2608:00AM
Oct-12-26
Oct-12-2603:28AM
Oct-08-26
Oct-08-2609:00AM
09:00AM
07:41AM
07:41AM
05:03AM
Oct-06-26
Oct-06-2606:15AM
Sep-18-26
Sep-16-26
Sep-16-2606:33AM
Sep-04-26
Sep-04-2609:08AM
Aug-27-26
Aug-25-26
Aug-18-26
Aug-18-2606:22PM
Aug-05-26
Company
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 86 | 77 | 65 | 62 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 29 | 29 | 21 | 19 | — | — | — | — | |
| Gross Profit | 58 | 48 | 44 | 43 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 96 | 85 | 76 | 82 | — | — | — | — | |
| Research and Development | 38 | 34 | 34 | 37 | — | — | — | — | |
| Other Operating Expense | -3 | 0 | 1 | -1 | — | — | — | — | |
| Operating Income | -73 | -71 | -67 | -75 | — | — | — | — | |
| Interest Expense | 8 | 5 | 2 | 1 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | -3 | 7 | -3 | — | — | — | — | |
| Net Income Before Taxes | -80 | -78 | -61 | -78 | — | — | — | — | |
| Income Taxes | 1 | 1 | 1 | 0 | — | — | — | — | |
| Consolidated Net Income | -80 | -79 | -62 | -79 | — | — | — | — | |
| Net Income From Continuing Operations | -80 | -79 | -62 | -79 | — | — | — | — | |
| Net Income | -80 | -79 | -62 | -79 | — | — | — | — | |
| EPS (Recurring) | -1.15 | -1.17 | -0.95 | -1.22 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.15 | -1.17 | -0.95 | -1.22 | — | — | — | — | |
| EPS (Diluted) | -1.15 | -1.17 | -0.95 | -1.22 | — | — | — | — | |
| EBITDA | -64 | -64 | -51 | -70 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.57 | 4.12 | 3.12 | 4.94 | — | — | — | — | |
| Gross Margin | 67.44 | 62.34 | 67.69 | 69.35 | — | — | — | — | |
| Operating Margin | -84.88 | -92.21 | -103.08 | -120.97 | — | — | — | — | |
| Net Margin | -93.02 | -102.60 | -95.38 | -127.42 | — | — | — | — | |
| Shares Outstanding | 74 | 68 | 66 | 65 | — | — | — | — | |
| Market Capitalization | 565 | 318 | 203 | 306 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Xu Zhenyu | Chief Scientific Officer | Oct 13 '26 | Sale | 7.18 | 4,000 | 28,727 | 541,493 | Oct 14 |
| Camblong Jurgi | Executive Chairman | Oct 12 '26 | Sale | 7.26 | 8,500 | 61,671 | 3,387,150 | Oct 14 |
| Menu Philippe | Chief Medical Officer | Oct 12 '26 | Sale | 7.26 | 5,000 | 36,303 | 195,993 | Oct 14 |
| Verma Abhimanyu | Chief Technology Officer | Oct 05 '26 | Sale | 8.12 | 5,284 | 42,929 | 166,887 | Oct 07 |
| Puylaert Kevin | Chief Sales Officer | Oct 05 '26 | Sale | 8.04 | 216 | 1,737 | 147,732 | Oct 07 |
| CARDOZA GEORGE | Chief Financial Officer | Oct 05 '26 | Sale | 8.10 | 1,592 | 12,897 | 306,726 | Oct 07 |
| Menu Philippe | Chief Medical Officer | Oct 05 '26 | Sale | 8.13 | 7,394 | 60,100 | 200,993 | Oct 07 |
| Xu Zhenyu | Chief Scientific Officer | Oct 05 '26 | Sale | 8.12 | 7,394 | 60,075 | 545,493 | Oct 07 |
| Muken Ross | Chief Executive Officer | Oct 05 '26 | Sale | 8.13 | 9,838 | 79,971 | 660,391 | Oct 07 |
| Camblong Jurgi | Executive Chairman | Oct 05 '26 | Sale | 8.13 | 40,172 | 326,526 | 3,395,650 | Oct 07 |
| Van Well Daan | Chief Legal Officer | Oct 05 '26 | Sale | 8.12 | 6,168 | 50,100 | 332,716 | Oct 07 |
| Valente Manuela | Chief People Officer | Oct 05 '26 | Sale | 8.13 | 4,240 | 34,487 | 206,210 | Oct 07 |
| CARDOZA GEORGE | Chief Financial Officer | Sep 21 '26 | Sale | 8.33 | 774 | 6,447 | 308,318 | Sep 22 |
| Muken Ross | Chief Executive Officer | Sep 21 '26 | Sale | 8.33 | 422 | 3,515 | 670,229 | Sep 22 |
| Menu Philippe | Chief Medical Officer | Sep 14 '26 | Sale | 7.88 | 5,000 | 39,417 | 208,387 | Sep 16 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.